SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Minerva Neurosciences Expects Roluperidone C19 Trial Results in Second Half of Next Year

Minerva Neurosciences Expects Roluperidone C19 Trial Results in Second Half of Next Year Minerva

NERV

Related stories